NYSEAMERICAN:BPMX - Biopharmx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.04 -0.22 (-17.46 %)
(As of 05/20/2019 06:00 AM ET)
Previous Close$1.04
Today's Range$0.98 - $1.11
52-Week Range$0.98 - $7.25
Volume1.09 million shs
Average Volume449,264 shs
Market Capitalization$9.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BPMX
CUSIPN/A
CIKN/A
Phone+1-650-8895020

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$9.08 million
Next Earnings Date6/6/2019 (Estimated)
OptionableNot Optionable

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

When did Biopharmx's stock split? How did Biopharmx's stock split work?

Biopharmx shares reverse split on the morning of Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) issued its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.25. The biotechnology company had revenue of $0.01 million for the quarter. View Biopharmx's Earnings History.

When is Biopharmx's next earnings date?

Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, June 6th 2019. View Earnings Estimates for Biopharmx.

What price target have analysts set for BPMX?

1 analysts have issued 1 year target prices for Biopharmx's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Biopharmx's stock price to reach $5.00 in the next year. This suggests a possible upside of 380.8% from the stock's current price. View Analyst Price Targets for Biopharmx.

What is the consensus analysts' recommendation for Biopharmx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.

Has Biopharmx been receiving favorable news coverage?

News coverage about BPMX stock has been trending somewhat positive on Monday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Are investors shorting Biopharmx?

Biopharmx saw a decline in short interest in April. As of April 15th, there was short interest totalling 4,383,786 shares, a decline of 19.8% from the March 29th total of 5,463,101 shares. Based on an average daily volume of 12,296,695 shares, the short-interest ratio is presently 0.4 days. Approximately 1.8% of the shares of the company are sold short. View Biopharmx's Current Options Chain.

Who are some of Biopharmx's key competitors?

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), CytRx (CYTR), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), AVEO Pharmaceuticals (AVEO) and Heat Biologics (HTBX).

Who are Biopharmx's key executives?

Biopharmx's management team includes the folowing people:
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
  • Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $1.04.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $9.08 million. Biopharmx employs 17 workers across the globe.

What is Biopharmx's official website?

The official website for Biopharmx is http://www.biopharmx.com.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  228 (Thanks for Voting!)
Underperform Votes:  140 (Thanks for Voting!)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel